Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 11046144 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
de Ruiter ND, et al. (2000) Ras-dependent regulation of c-Jun phosphorylation is mediated by the Ral guanine nucleotide exchange factor-Ral pathway. Mol Cell Biol 20, 8480-8 11046144
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

T308-p - Akt1 (mouse)
Orthologous residues
Akt1 (human): T308‑p, Akt1 (mouse): T308‑p, Akt1 (rat): T308‑p, Akt1 (fruit fly): T423‑p, Akt1 (cow): T308‑p
Characterization
 Methods used to characterize site in vivo [32P] bio-synthetic labeling, phospho-antibody, phosphopeptide mapping, western blotting
 Relevant cell lines - cell types - tissues:  293 (epithelial), 3T3 (fibroblast) [InsR (human)]
 Cellular systems studied:  cell lines
 Species studied:  human, mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
PD98059 insulin no effect upon treatment-induced increase
LY294002 insulin inhibit treatment-induced increase

S72-p - ATF-2 (mouse)
Orthologous residues
ATF‑2 (human): S90‑p, ATF‑2 (mouse): S72‑p, ATF‑2 (rat): S72‑p
Characterization
 Methods used to characterize site in vivo [32P] bio-synthetic labeling, phospho-antibody, phosphopeptide mapping, western blotting
 Relevant cell lines - cell types - tissues:  293 (epithelial), 3T3 (fibroblast) [InsR (human)]
 Cellular systems studied:  cell lines
 Species studied:  human, mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase

T203-p - ERK1 (mouse)
Orthologous residues
ERK1 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
 Methods used to characterize site in vivo [32P] bio-synthetic labeling, phospho-antibody, phosphopeptide mapping, western blotting
 Relevant cell lines - cell types - tissues:  293 (epithelial), 3T3 (fibroblast) [InsR (human)]
 Cellular systems studied:  cell lines
 Species studied:  human, mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
PD98059 insulin inhibit treatment-induced increase
LY294002 insulin no effect upon treatment-induced increase
PP1 insulin no effect upon treatment-induced increase
HRas (mouse) increase activated
EGF increase
PP1 EGF no effect upon treatment-induced increase

Y205-p - ERK1 (mouse)
Orthologous residues
ERK1 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
 Methods used to characterize site in vivo [32P] bio-synthetic labeling, phospho-antibody, phosphopeptide mapping, western blotting
 Relevant cell lines - cell types - tissues:  293 (epithelial), 3T3 (fibroblast) [InsR (human)]
 Cellular systems studied:  cell lines
 Species studied:  human, mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
PD98059 insulin inhibit treatment-induced increase
LY294002 insulin no effect upon treatment-induced increase
PP1 insulin no effect upon treatment-induced increase
HRas (mouse) increase activated
EGF increase
PP1 EGF no effect upon treatment-induced increase

T183-p - ERK2 (mouse)
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p
Characterization
 Methods used to characterize site in vivo [32P] bio-synthetic labeling, phospho-antibody, phosphopeptide mapping, western blotting
 Relevant cell lines - cell types - tissues:  293 (epithelial), 3T3 (fibroblast) [InsR (human)]
 Cellular systems studied:  cell lines
 Species studied:  human, mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
PD98059 insulin inhibit treatment-induced increase
LY294002 insulin no effect upon treatment-induced increase
PP1 insulin no effect upon treatment-induced increase
HRas (mouse) increase activated
EGF increase
PP1 EGF no effect upon treatment-induced increase

Y185-p - ERK2 (mouse)
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p
Characterization
 Methods used to characterize site in vivo [32P] bio-synthetic labeling, phospho-antibody, phosphopeptide mapping, western blotting
 Relevant cell lines - cell types - tissues:  293 (epithelial), 3T3 (fibroblast) [InsR (human)]
 Cellular systems studied:  cell lines
 Species studied:  human, mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
PD98059 insulin inhibit treatment-induced increase
LY294002 insulin no effect upon treatment-induced increase
PP1 insulin no effect upon treatment-induced increase
HRas (mouse) increase activated
EGF increase
PP1 EGF no effect upon treatment-induced increase

T183-p - JNK1 (mouse)
Orthologous residues
JNK1 (human): T183‑p, JNK1 iso2 (human): T183‑p, JNK1 iso3 (human): T183‑p, JNK1 (mouse): T183‑p, JNK1 (rat): T183‑p
Characterization
 Methods used to characterize site in vivo [32P] bio-synthetic labeling, phospho-antibody, phosphopeptide mapping, western blotting
 Relevant cell lines - cell types - tissues:  293 (epithelial), 3T3 (fibroblast) [InsR (human)]
 Cellular systems studied:  cell lines
 Species studied:  human, mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase

Y185-p - JNK1 (mouse)
Orthologous residues
JNK1 (human): Y185‑p, JNK1 iso2 (human): Y185‑p, JNK1 iso3 (human): Y185‑p, JNK1 (mouse): Y185‑p, JNK1 (rat): Y185‑p
Characterization
 Methods used to characterize site in vivo [32P] bio-synthetic labeling, phospho-antibody, phosphopeptide mapping, western blotting
 Relevant cell lines - cell types - tissues:  293 (epithelial), 3T3 (fibroblast) [InsR (human)]
 Cellular systems studied:  cell lines
 Species studied:  human, mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase

S63-p - Jun (mouse)
Orthologous residues
Jun (human): S63‑p, Jun (mouse): S63‑p, Jun (rat): S63‑p
Characterization
 Methods used to characterize site in vivo [32P] bio-synthetic labeling, phospho-antibody, phosphopeptide mapping, western blotting
 Relevant cell lines - cell types - tissues:  293 (epithelial), 3T3 (fibroblast) [InsR (human)]
 Cellular systems studied:  cell lines
 Species studied:  human, mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
RLF (mouse) increase activated

S73-p - Jun (mouse)
Orthologous residues
Jun (human): S73‑p, Jun (mouse): S73‑p, Jun (rat): S73‑p
Characterization
 Methods used to characterize site in vivo [32P] bio-synthetic labeling, phospho-antibody, phosphopeptide mapping, western blotting
 Relevant cell lines - cell types - tissues:  293 (epithelial), 3T3 (fibroblast) [InsR (human)]
 Cellular systems studied:  cell lines
 Species studied:  human, mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
insulin HRas (mouse) inhibit treatment-induced increase dominant negative
PD98059 insulin no effect upon treatment-induced increase
LY294002 insulin no effect upon treatment-induced increase
insulin RalB (mouse) inhibit treatment-induced increase dominant negative
insulin RALBP1 (mouse) inhibit treatment-induced increase dominant negative
insulin RalGDS (human) inhibit treatment-induced increase dominant negative
PP1 insulin inhibit treatment-induced increase
RLF (mouse) increase activated
EGF increase
EGF RalB (mouse) inhibit treatment-induced increase dominant negative
PP1 EGF inhibit treatment-induced increase


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.